“Skin Clearance, Duration of Treatment-Free Interval, and Safety of Tapinarof Cream 1% Once Daily: Results from ADORING 3, a 48-Week Phase 3 Trial in Adults and Children Down to 2 Years of Age With Atopic Dermatitis”. SKIN The Journal of Cutaneous Medicine 9, no. 2 (March 17, 2025): s553. Accessed May 1, 2026. https://skin.dermsquared.com/skin/article/view/3285.